The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Feb. 15, 2022
Filed:
Jun. 24, 2016
Applicant:
Jcr Pharmaceuticals Co., Ltd., Hyogo, JP;
Inventors:
Hiroyuki Sonoda, Hyogo, JP;
Kenichi Takahashi, Hyogo, JP;
Assignee:
JCR Pharmaceuticals Co., Ltd., Hyogo, JP;
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C07K 16/28 (2006.01); C12N 9/16 (2006.01); A61K 39/395 (2006.01); C12N 9/10 (2006.01); C07K 19/00 (2006.01); C07K 14/475 (2006.01); C12N 5/10 (2006.01); A61K 45/00 (2006.01); C07K 16/46 (2006.01); C07K 16/18 (2006.01); C12N 15/09 (2006.01); C12N 9/64 (2006.01); C12N 9/24 (2006.01); C12N 15/113 (2010.01); A61P 25/00 (2006.01); C07K 14/505 (2006.01); C07K 14/715 (2006.01); C12N 9/14 (2006.01); C12N 9/48 (2006.01); A61K 39/00 (2006.01);
U.S. Cl.
CPC ...
C07K 16/28 (2013.01); A61K 39/395 (2013.01); A61K 45/00 (2013.01); A61P 25/00 (2018.01); C07K 14/475 (2013.01); C07K 14/505 (2013.01); C07K 14/7151 (2013.01); C07K 16/18 (2013.01); C07K 16/46 (2013.01); C07K 19/00 (2013.01); C12N 5/10 (2013.01); C12N 9/10 (2013.01); C12N 9/14 (2013.01); C12N 9/16 (2013.01); C12N 9/24 (2013.01); C12N 9/2402 (2013.01); C12N 9/48 (2013.01); C12N 9/64 (2013.01); C12N 15/09 (2013.01); C12N 15/113 (2013.01); C12Y 301/02 (2013.01); C12Y 302/01076 (2013.01); C12Y 304/14009 (2013.01); C12Y 310/01001 (2013.01); A61K 2039/505 (2013.01); C07K 2317/24 (2013.01); C07K 2317/92 (2013.01); C07K 2319/30 (2013.01);
Abstract
Disclosed are a means to convert compounds having physiological or pharmacological activity and unable to pass through the blood-brain barrier into a form that allows them to pass through the blood-brain barrier, and compounds converted thereby. The means is an anti-human transferrin receptor antibody and the converted compounds are molecular conjugates between physiologically active protein or pharmacologically active low-molecular-weight compounds and an anti-human transferrin receptor antibody.